What is the pharmacokinetic/pharmacodynamic relationship of Argatroban?
When Argatroban is administered by continuous infusion, anticoagulant effects and plasma concentrations of argatroban follow similar, predictable temporal response profiles, with low intersubject variability. Immediately upon initiation of infusion of Argatroban, anticoagulant effects are produced as concentrations of plasma argatroban begin to rise. Steady-state levels of both drug and anticoagulant effect are typically attained within 1 to 3 hours and are maintained until the infusion is discontinued or the dosage adjusted. Steady-state concentrations of plasma argatroban increase proportionally with dose (for infusion doses up to 40 mcg/kg/min in healthy subjects) and are well correlated with steady-state anticoagulant effects. For infusion doses up to 40 mcg/kg/min, Argatroban increases, in a dose-dependent fashion, the aPTT, the ACT, the prothrombin time (PT), the International Normalized Ratio (INR), and the thrombin time (TT) in healthy volunteers and cardiac patients. Represent
Related Questions
- how does the pharmacokinetic/pharmacodynamic profile for cortisol suppression compare with an aqueous suspension-based formulation?
- Do plasma concentrations obtained from early arterial blood sampling improve pharmacokinetic/pharmacodynamic modeling?
- What is the pharmacokinetic/pharmacodynamic relationship of Argatroban?
